Back to Search
Start Over
Complete response to tremelimumab plus durvalumab treatment in hepatocellular carcinoma with a bile duct tumor thrombus: A case report.
- Source :
- Oncology Letters; Jul2024, Vol. 28 Issue 1, pN.PAG-N.PAG, 1p
- Publication Year :
- 2024
-
Abstract
- Tremelimumab plus durvalumab (Dur/Tre) is the first-line treatment for advanced hepatocellular carcinoma (HCC) worldwide. The present report describes the case of a 68-year-old man diagnosed with advanced HCC and a bile duct tumor thrombus (BDTT) who achieved a complete response to Dur/Tre therapy. The BDTT progressed to the bifurcation of the left and right hepatic ducts. Over time, both the tumors and BDTT progressively decreased in size, and a complete response was confirmed using the Response Evaluation Criteria in Solid Tumors (version 1.1.) 6 months after treatment administration. Subsequently, immune-related adverse events, including type 1 diabetes mellitus and diabetic ketoacidosis, emerged, leading to treatment discontinuation. The patient was undergoing outpatient follow-up in a drug-free state with no signs of recurrence 290 days after the initial administration of Dur/Tre. Although long-term and meticulous observations are required, the present findings could influence the choice of systemic chemotherapy for advanced HCC. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17921074
- Volume :
- 28
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Oncology Letters
- Publication Type :
- Academic Journal
- Accession number :
- 177774762
- Full Text :
- https://doi.org/10.3892/ol.2024.14465